WHO ICTRP trial
A PHASE 2, MULTICENTER, OPEN-LABEL, 2-COHORT STUDY OF TRASTUZUMAB DERUXTECAN…
NL-OMON54783 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON54783 |
|---|---|
| Public title | A PHASE 2, MULTICENTER, OPEN-LABEL, 2-COHORT STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201a), AN ANTI-HER2 ANTIBODY DRUG CONJUGATE (ADC), FOR HER2-OVER-EXPRESSING OR -MUTATED, UNRESECTABLE AND/OR METASTATIC NONSMALL CELL LUNG CANCER (NSCLC) |
| Scientific title | A PHASE 2, MULTICENTER, OPEN-LABEL, 2-COHORT STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201a), AN ANTI-HER2 ANTIBODY DRUG CONJUGATE (ADC), FOR HER2-OVER-EXPRESSING OR -MUTATED, UNRESECTABLE AND/OR METASTATIC NONSMALL CELL LUNG CANCER (NSCLC) - DS8201-A-U204 |
| Primary sponsor | DAIICHI SANKYO, INC. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Japan;Netherlands;United States of America |
| Conditions | Lung Caner Metastatic Non-Small Cell Lung Cancer;10038666;Lung Caner;Metastatic Non-Small Cell Lung Cancer |
| Interventions | There will be subjects allocated to two different cohorts according to the centrally confirmed HER2 IHC status and documented HER2 mutation status. All subjects will receive trastuzumab deruxtecan treatment of the 6.4 mg/kg Q3W. ;Metastatic… |
| Registration date | Jul 18, 2023 |
| Target size | 31 |
| Secondary IDs | 2017-004781-94;NL65483.031.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: